TuHURA Biosciences Completes Acquisition of Kineta, Inc.

TuHURA Biosciences ( (HURA) ) has issued an update.

On June 30, 2025, TuHURA Biosciences completed its acquisition of Kineta, Inc., following a series of mergers that began with an agreement on December 11, 2024. This acquisition included the rights to Kineta’s novel antibody, TBS-2025, and was executed through a combination of cash and stock. The mergers were accounted for as a business combination under U.S. GAAP, and TuHURA has provided pro forma financial statements to reflect these transactions as if they had occurred on January 1, 2024. This strategic move is expected to enhance TuHURA’s market position and operational capabilities.

The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.

Spark’s Take on HURA Stock

According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.

TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.

To see Spark’s full report on HURA stock, click here.

More about TuHURA Biosciences

TuHURA Biosciences, Inc., a Nevada corporation, operates in the biosciences industry. The company focuses on developing innovative therapies and has recently expanded its portfolio through strategic mergers and acquisitions.

Average Trading Volume: 211,144

Technical Sentiment Signal: Sell

Current Market Cap: $104.8M

For a thorough assessment of HURA stock, go to TipRanks’ Stock Analysis page.